Company Snapshot

Investment Thesis

Merck extends growth beyond Keytruda with late-stage oncology combinations, vaccine leadership, and animal health strength. Patent cliffs are mitigated by a rich pipeline and business development focused on oncology, immunology, and cardiometabolic disease.

  • Keytruda Durability: New adjuvant indications and subcutaneous formulations extend exclusivity and patient access.
  • Vaccine Momentum: Gardasil and V116 pneumonia vaccines deliver double-digit growth and global expansion.
  • Pipeline Depth: Over 30 late-stage assets, including sotatercept and MK-3475 combos, diversify revenue.

Revenue Mix

Oncology 51% of FY24 revenue
Vaccines 18% — Gardasil, Pneumovax
Animal Health 11% — livestock & companion
Other Human Health 20% — hospital & specialty

Mix reflects Merck fiscal year 2024 continuing operations.

Recent Performance

MTD -1.91%
QTD -6.42%
YTD -14.95%
5Y +9.72%

Merck eased to $88.00 as investors digested upcoming Keytruda biosimilar risks, yet positive data for sotatercept and next-gen antibody-drug conjugates support longer-term growth.

Strategic Insights

Keytruda Lifecycle

Subcutaneous formulations, perioperative approvals, and combinations with TIGIT inhibitors extend the blockbuster’s runway.

Vaccine Growth

High-demand franchises like Gardasil benefit from increased manufacturing capacity and expanded age indications.

Business Development

Targeted acquisitions (Prometheus, Acceleron) add differentiated assets in immunology and cardiometabolic segments.

Latest Coverage

Curated headlines sourced from Maxim’s AI newsroom.

Loading latest coverage...